Arcus Biosciences (RCUS) EBITDA Margin (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly EBITDA Margin of 788.24% for Q1 2026, down 35252.0% year-over-year from N/an in Q1 2025, and down 128.17% quarter-over-quarter from 345.45% in Q4 2025.
Arcus Biosciences (RCUS) EBITDA Margin (2017 - 2026) Analysis & Trends
Arcus Biosciences' EBITDA Margin history runs 10 years deep, the most recent figure standing at 788.24% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 35252.0% year-over-year to 788.24%; the TTM figure through Mar 2026 stood at 168.64% (up 14058.0% YoY), while the FY2025 annual figure was 156.28%, down 2837.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 788.24%, down from 345.45% in the prior quarter.
- The five-year high for EBITDA Margin was 5.0% in Q2 2025, with the low at 788.24% in Q1 2026.
- The 5-year median for EBITDA Margin is 286.21% (2023), against an average of 329.77%.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin surged 61375 bps in 2022, then plunged 43235 bps in 2023.
- Arcus Biosciences' EBITDA Margin stood at 217.65% in 2022, then sank by 199 bps to 650.0% in 2023, then jumped by 39 bps to 396.15% in 2024, then gained by 13 bps to 345.45% in 2025, then slumped by 128 bps to 788.24% in 2026.
- Business Quant data shows RCUS's EBITDA Margin at 788.24% in Q1 2026, 345.45% in Q4 2025, and 546.15% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -234.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -234.15% |
| Mar 31, 2026 | -788.24% |
| Dec 31, 2025 | -345.45% |
| Sep 30, 2025 | -546.15% |
| Jun 30, 2025 | -5.00% |
| Mar 31, 2025 | -435.71% |
| Dec 31, 2024 | -396.15% |
| Sep 30, 2024 | -218.75% |
| Jun 30, 2024 | -271.79% |
| Mar 31, 2024 | -11.03% |
| Dec 31, 2023 | -650.00% |
| Sep 30, 2023 | -250.00% |
| Jun 30, 2023 | -286.21% |
| Mar 31, 2023 | -344.00% |
| Dec 31, 2022 | -217.65% |
| Sep 30, 2022 | -212.12% |
| Jun 30, 2022 | -255.56% |
| Mar 31, 2022 | -372.22% |
| Dec 31, 2021 | 79.25% |
| Sep 30, 2021 | -825.87% |